129 related articles for article (PubMed ID: 33074046)
1. Response of breast cancer carcinoma spheroids to combination therapy with radiation and DNA-PK inhibitor: growth arrest without a change in
Yu J; Lu R; Nedrow JR; Sgouros G
Int J Radiat Biol; 2020 Dec; 96(12):1534-1540. PubMed ID: 33074046
[TBL] [Abstract][Full Text] [Related]
2. Radio-sensitization of human leukaemic MOLT-4 cells by DNA-dependent protein kinase inhibitor, NU7441.
Tichy A; Durisova K; Salovska B; Pejchal J; Zarybnicka L; Vavrova J; Dye NA; Sinkorova Z
Radiat Environ Biophys; 2014 Mar; 53(1):83-92. PubMed ID: 24100951
[TBL] [Abstract][Full Text] [Related]
3. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Radiosensitizing Effect of ATR, ATM and DNA-PK Kinase Inhibitors on Cervical Carcinoma Cells.
Vávrová J; Zárybnická L; Jošt P; Tichý A; Řezáčová M; Šinkorová Z; Pejchal J
Folia Biol (Praha); 2016; 62(4):167-74. PubMed ID: 27643582
[TBL] [Abstract][Full Text] [Related]
6. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair.
Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B
Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644
[TBL] [Abstract][Full Text] [Related]
8. Effect of resveratrol on the radiosensitivity of 5-FU in human breast cancer MCF-7 cells.
Aghamiri S; Jafarpour A; Zandsalimi F; Aghemiri M; Shoja M
J Cell Biochem; 2019 Sep; 120(9):15671-15677. PubMed ID: 31069826
[TBL] [Abstract][Full Text] [Related]
9. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086
[TBL] [Abstract][Full Text] [Related]
10. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
[TBL] [Abstract][Full Text] [Related]
11. Lithium increases radiosensitivity by abrogating DNA repair in breast cancer spheroid culture.
Rouhani M; Goliaei B; Khodagholi F; Nikoofar A
Arch Iran Med; 2014 May; 17(5):352-60. PubMed ID: 24784865
[TBL] [Abstract][Full Text] [Related]
12. 3D tumour spheroids for the prediction of the effects of radiation and hyperthermia treatments.
Brüningk SC; Rivens I; Box C; Oelfke U; Ter Haar G
Sci Rep; 2020 Feb; 10(1):1653. PubMed ID: 32015396
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitivity, repair capacity, and stem cell fraction in human soft tissue tumors: an in vitro study using multicellular spheroids and the colony assay.
Stuschke M; Budach V; Klaes W; Sack H
Int J Radiat Oncol Biol Phys; 1992; 23(1):69-80. PubMed ID: 1572832
[TBL] [Abstract][Full Text] [Related]
14. Radioresponsiveness of human glioma, sarcoma, and breast cancer spheroids depends on tumor differentiation.
Stuschke M; Budach V; Sack H
Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):627-36. PubMed ID: 8226158
[TBL] [Abstract][Full Text] [Related]
15. Changes in the response of MCF-7 cells to ionizing radiation after the combination of ATM and DNA-PK inhibition.
Ćmielová J; Havelek R; Vávrová J; Řezáčová M
Med Oncol; 2015 May; 32(5):138. PubMed ID: 25801233
[TBL] [Abstract][Full Text] [Related]
16. Multimodality therapy: radiation and continuous concomitant cis-platinum and PKC inhibition in a cervical carcinoma model.
Sommers GM; Alfieri AA
Cancer Invest; 1998; 16(7):462-70. PubMed ID: 9774953
[TBL] [Abstract][Full Text] [Related]
17. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.
Halfter K; Hoffmann O; Ditsch N; Ahne M; Arnold F; Paepke S; Grab D; Bauerfeind I; Mayer B
J Transl Med; 2016 May; 14(1):112. PubMed ID: 27142386
[TBL] [Abstract][Full Text] [Related]
18. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.
Phillips TM; McBride WH; Pajonk F
J Natl Cancer Inst; 2006 Dec; 98(24):1777-85. PubMed ID: 17179479
[TBL] [Abstract][Full Text] [Related]
19. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
